ArticleStem cell research & therapy2026
EXO-VNN2 derived from 3D-cultured DPSCs enhances the inflammatory response of PDLSCs and suppresses bone regeneration in periodontitis.
Article in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAs a chronic inflammatory disease characterized by periodontal tissue destruction, periodontitis has a pathogenesis that remains incompletely understood. This study aimed to investigate the expression of upregulated vanin-2 (VNN2) in exosomes derived from dental pulp stem cells (DPSCs) and its effects on the function of periodontal ligament stem cells (PDLSCs) and the progression of periodontitis.
methodsA total of 35 patients with periodontitis and 35 healthy individuals were enrolled for gingival tissue sample collection. DPSC-EXO-VNN2 was cultured with a 3D system and isolated by ultracentrifugation. The samples were then subjected to nanoparticle tracking analysis (NTA), western blot and transmission electron microscopy (TEM). In vitro, PDLSCs were treated with DPSC- EXO-VNN2 and LPS, and the expression of IL-6 and TNF-α and their osteogenic potential were evaluated. Furthermore, in vivo, experimental periodontitis was induced in rats, which were then divided into two groups and treated with either DPSC-EXO-VNN2 or PBS. The maxillae were subsequently collected for histological staining and micro-CT analysis.
resultsVNN2 was upregulated in periodontitis according to dataset analysis, western blot and immunofluorescence (P < 0.05). Higher expression levels of VNN2 were associated with greater periodontal parameters PD and CAL (P < 0.05). The production of DPSC-EXO in the 3D culture system surpassed that in the 2D system. In vitro, PDLSCs internalized 3D-DPSC-EXO-VNN2, which increased LPS-induced IL-6 and TNF-α production while reducing osteogenic differentiation, as shown by decreased ALP activity and mineralization. In vivo, DPSC-EXO-VNN2 administration worsened alveolar bone loss, as micro-CT revealed a significantly lower bone volume fraction (P < 0.01) than did the control treatment.
conclusionThis study reveals for the first time that DPSC-EXO-VNN2 participates in the progression of periodontitis by regulating the inflammatory response and osteogenic differentiation ability of PDLSCs. Future research may further explore the potential application of targeting VNN2 in treating periodontitis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.